Your email has been successfully added to our mailing list.

×
0.00650406504065041 0.00650406504065041 0.00650406504065041 0.00650406504065041 0.00650406504065041 0.00650406504065041 0.00650406504065041 -0.0292682926829268
Stock impact report

GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea

Entasis Therapeutics Holdings Inc. (ETTX) 
Last entasis therapeutics holdings inc. earnings: 11/14 07:30 am Check Earnings Report
Company Research Source: GlobeNewswire
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections estimated each year; Neisseria gonorrhoeae increasingly resistant to globally recommended treatments and classified by the World Health Organization as a priority pathogen GENEVA and WALTHAM, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organization developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today jointly announced the initiation of a global phase 3 pivotal trial of zoliflodacin. Zoliflodacin is a novel, first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhea. Following positive phase 2 results pre Show less Read more
Impact Snapshot
Event Time:
ETTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ETTX alerts
Opt-in for
ETTX alerts

from News Quantified
Opt-in for
ETTX alerts

from News Quantified